Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor for Anti-Angiogenic Cancer Research

Executive Summary: Anlotinib hydrochloride is a next-generation small-molecule inhibitor targeting VEGFR2, PDGFRβ, and FGFR1 with nanomolar potency, validated in multiple preclinical models for its anti-angiogenic effects (Chen & Feng, 2019). It demonstrates superior inhibition of endothelial cell migration and capillary tube formation compared to sunitinib and sorafenib in vitro. The compound exhibits high oral bioavailability (41–77% in dogs; 28–58% in rats), high plasma protein binding (93% in humans), and broad tissue distribution, including tumor and brain tissue. Safety studies indicate a high median lethal dose (LD₅₀ 1735.9 mg/kg, oral, 14 days) and low systemic toxicity. APExBIO supplies Anlotinib hydrochloride (C8688) for rigorous research applications (product page).

Biological Rationale

Angiogenesis is crucial for tumor growth and metastasis. Tyrosine kinase signaling pathways, particularly those mediated by VEGFR2, PDGFRβ, and FGFR1, regulate endothelial cell proliferation and migration. Inhibiting these kinases disrupts tumor neovascularization, restricting cancer progression. Anlotinib hydrochloride was engineered to target these kinases simultaneously, addressing intrinsic redundancy in angiogenic signaling (Chen & Feng, 2019). Its broad-spectrum activity positions it as a central tool for dissecting angiogenesis mechanisms in cancer research.

Mechanism of Action of Anlotinib (hydrochloride)

Anlotinib hydrochloride is a small-molecule multi-target tyrosine kinase inhibitor (TKI). It directly inhibits VEGFR2 (IC₅₀ = 5.6 ± 1.2 nM), PDGFRβ (IC₅₀ = 8.7 ± 3.4 nM), and FGFR1 (IC₅₀ = 11.7 ± 4.1 nM) (APExBIO). By blocking ATP binding to the kinase domains, it suppresses downstream signaling via the ERK pathway. This leads to marked inhibition of VEGF/PDGF-BB/FGF-2-induced endothelial cell migration and capillary tube formation. Anlotinib can also inhibit related kinases such as c-Kit and Met, extending its spectrum of anti-angiogenic activity (Chen & Feng, 2019).

Evidence & Benchmarks

• Anlotinib suppresses endothelial cell migration in vitro in a concentration-dependent manner (IC₅₀ values: VEGFR2 5.6 nM, PDGFRβ 8.7 nM, FGFR1 11.7 nM) (APExBIO).
• In preclinical angiogenesis assays, anlotinib outperforms sunitinib, sorafenib, and nintedanib in inhibiting capillary-like tube formation (Prescission, 2023).
• It demonstrates rapid oral absorption (bioavailability 28–58% in rats, 41–77% in dogs) and a high volume of distribution in animal models (Chen & Feng, 2019).
• Clinical case reports show tumor regression in metastatic intra-abdominal desmoplastic small round cell tumor (IADSRCT) upon anlotinib treatment, with manageable toxicity (hypertriglyceridemia, fatigue) (Chen & Feng, 2019).
• High plasma protein binding (93% in humans) and broad tissue distribution, including lung, liver, kidney, heart, and tumor, with blood-brain barrier penetration (APExBIO).
• Safety evaluations reveal a 14-day oral LD₅₀ of 1735.9 mg/kg in rodents, with no significant organ or genetic toxicity at research-relevant doses (Chen & Feng, 2019).

This article extends the mechanistic analysis found in "Anlotinib Hydrochloride: Redefining Tumor Angiogenesis Research" by providing updated quantitative pharmacokinetic and safety data. It also clarifies the superior selectivity profile compared to earlier benchmarks discussed in "Applied Cancer Research with Anlotinib Hydrochloride".

Applications, Limits & Misconceptions

Anlotinib hydrochloride is used in cellular assays, particularly with human vascular endothelial cells (EA.hy 926), to evaluate anti-angiogenic mechanisms, cell migration, and ERK signaling modulation. It is suitable for capillary tube formation assays and high-content angiogenesis screens. The compound is not approved for diagnostic or therapeutic human use and is for research-only applications. Its use in genetic models or non-angiogenic pathways requires further validation.

Common Pitfalls or Misconceptions

• Not a diagnostic or therapeutic agent: Anlotinib hydrochloride from APExBIO is strictly for research use only.
• Does not inhibit all tyrosine kinases: Selectivity is high for VEGFR2, PDGFRβ, FGFR1, but not universal across the kinome.
• Requires CYP3A metabolism: Models lacking CYP3A activity may show altered pharmacokinetics.
• Not validated in non-vascular cell lines: Most published data are from endothelial or cancer cell models; results may not extrapolate to unrelated cell types.
• Species differences: Pharmacokinetic and toxicity profiles may differ between rodents, dogs, and humans.

Workflow Integration & Parameters

Anlotinib hydrochloride (C8688) is supplied by APExBIO as a lyophilized powder for reconstitution. It should be stored at –20°C under desiccation. Typical in vitro working concentrations range from 1 nM to 1 μM for kinase or cell-based assays. For migration and tube formation assays, EC₅₀ values guide dosing. Metabolic stability and CYP3A interactions should be considered in pharmacokinetic research. For detailed assay protocols leveraging its superior selectivity, see the C8688 kit page (Anlotinib (hydrochloride)).

Conclusion & Outlook

Anlotinib hydrochloride is a validated, high-potency, multi-target tyrosine kinase inhibitor for advanced anti-angiogenic and cancer research. Its superior selectivity, favorable pharmacokinetic profile, and robust safety margins enable reproducible in vitro and in vivo studies of tumor angiogenesis inhibition. Future research should further dissect its activity spectrum and optimize translational models. For more on molecular mechanisms, see "Anlotinib Hydrochloride: Advanced Multi-Target Tyrosine Kinase Signaling Dissection", which this article updates with expanded safety and PK findings.